Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time today, please press star zero, and a member of our team will be happy to help you. ¶¶ ¶¶ Thank you. © transcript Emily Beynon Again, ladies and gentlemen, thank you for your continued patience. Your meeting will begin shortly. Again, if you do need assistance at any time today, please press star zero, and a member of our team will be happy to help you. ¶¶ . . . . . © transcript Emily Beynon Hello and welcome everyone joining today's Maravai Life Sciences Q4 2025 Results Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Deb Hart. Please go ahead. Good afternoon, everyone. Thanks for joining us on our fourth quarter and year-end 2025 earnings call. The press release and slides accompanying today's call are posted on our website and available at investors.maravai.com. As you can see from the agenda on slide two, our CEO, Vern Brust, will provide a business update, and our CFO, Raj Asaprota, will review our financial results. Dr. Chan-Seng Zhao, our chief scientific officer, will join us for our Q&A session. Turning to slide three, I'd like to note that we have renamed our two reportable segments from nucleic acid production and biologic safety testing to Trilink and Cygnus, respectively. This changes to better align with our brands and internal operating terminology. There have been no changes to th...